These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7518974)

  • 1. Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506.
    Mueller AR; Platz KP; Bechstein WO; Schattenfroh N; Stoltenburg-Didinger G; Blumhardt G; Christe W; Neuhaus P
    Transplantation; 1994 Jul; 58(2):155-70. PubMed ID: 7518974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506.
    Platz KP; Mueller AR; Blumhardt G; Bachmann S; Bechstein WO; Kahl A; Neuhaus P
    Transplantation; 1994 Jul; 58(2):170-8. PubMed ID: 7518975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity versus rejection--or why conversions between cyclosporine A and FK506 were performed after liver transplantation.
    Platz KP; Mueller AR; Jonas S; Blumhardt G; Bechstein WO; Lobeck H; Neuhaus HL
    Clin Transplant; 1995 Jun; 9(3 Pt 1):146-54. PubMed ID: 7549052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine A or FK506?
    Mueller AR; Platz KP; Blumhardt G; Bechstein WO; Steinmüller T; Christe W; Hopf U; Lobeck H; Neuhaus P
    Clin Transplant; 1995 Jun; 9(3 Pt 1):176-84. PubMed ID: 7549057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
    Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
    Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial.
    McDiarmid SV; Busuttil RW; Ascher NL; Burdick J; D'Alessandro AM; Esquivel C; Kalayoglu M; Klein AS; Marsh JW; Miller CM
    Transplantation; 1995 Feb; 59(4):530-6. PubMed ID: 7533345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression.
    Hadley S; Samore MH; Lewis WD; Jenkins RL; Karchmer AW; Hammer SM
    Transplantation; 1995 Mar; 59(6):851-9. PubMed ID: 7535482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study.
    Rinaldi M; Pellegrini C; Martinelli L; Goggi C; Gavazzi A; Campana C; Arbustini E; Grossi P; Regazzi M; Ippoliti G; Vigano M
    J Heart Lung Transplant; 1997 Oct; 16(10):1001-10. PubMed ID: 9361242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up.
    Greig P; Lilly L; Scudamore C; Erb S; Yoshida E; Kneteman N; Bain V; Ghent C; Marotta P; Grant D; Wall W; Tchervenkov J; Barkun J; Roy A; Marleau D; McAlister V; Peltekian K
    Liver Transpl; 2003 Jun; 9(6):587-95. PubMed ID: 12783400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
    Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
    Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience.
    Neuhaus P; Blumhardt G; Bechstein WO; Platz KP; Jonas S; Mueller AR; Langrehr JM; Lohmann R; Schattenfroh N; Knoop M
    Transplantation; 1995 Jan; 59(1):31-40. PubMed ID: 7530868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postural hand tremor before and following liver transplantation and immunosuppression with cyclosporine or tacrolimus in patients without clinical signs of hepatic encephalopathy.
    Paul F; Müller J; Christe W; Steinmüller T; Poewe W; Wissel J
    Clin Transplant; 2004 Aug; 18(4):429-33. PubMed ID: 15233821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotoxicity after orthotopic liver transplantation in cyclosporin A- and FK 506-treated patients.
    Mueller AR; Platz KP; Schattenfroh N; Bechstein WO; Christe W; Neuhaus P
    Transpl Int; 1994; 7 Suppl 1():S37-42. PubMed ID: 11271254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study.
    Lerut JP; Ciccarelli O; Mauel E; Gheerardhyn R; Talpe S; Sempoux C; Laterre PF; Roggen FM; Van Leeuw V; Otte JB; Gianello P
    Transpl Int; 2001 Dec; 14(6):420-8. PubMed ID: 11793040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of tacrolimus in postoperative treatment of patients with renal transplantation for diabetic end-stage renal disease].
    Yu LX; Shan HT; Fu SJ; Du CF; Ma JJ; Xu J; Deng WF; Wang YB
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1146-8. PubMed ID: 14625173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of cyclosporine microemulsion and tacrolimus in 39 recipients of living donor liver transplantation.
    Tanaka K; Lake J; Villamil F; Levy G; Marotta P; Mies S; de Hemptinne B; Moench C
    Liver Transpl; 2005 Nov; 11(11):1395-402. PubMed ID: 16237691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
    Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Slowing progression of chronic allograft nephropathy by conversion from cyclosporin A to tacrolimus].
    Peng LK; Xie XB; Peng FH; Wang Y; Jiang Y; Lan GB; Fang CH; Nie MH
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):59-62. PubMed ID: 17344588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.